Market Cap: $25.43B
UC
United Therapeutics Corporation
UTHR
NASDAQ (NASDAQ Global Select)USD
Market Cap: $25.43B
United Therapeutics Corporation (Ticker: UTHR) recently hurdles financial challenges but simultaneously showcases advancements in its clinical pipeline. The company's first-quarter earnings report hig…
United Therapeutics (Ticker: UTHR) has achieved a major milestone in its efforts to combat pulmonary diseases with the successful results from its TETON-1 phase 3 study. This trial focused on nebulize…
United Therapeutics (Ticker: UTHR) is at the forefront of innovation in the treatment of pulmonary diseases, with recent successes in clinical research significantly enhancing its profile in the bioph…
United Therapeutics (Ticker: UTHR) continues to make waves in the biotechnology sector with its innovative approach to treating pulmonary arterial hypertension (PAH) and advancing organ transplantatio…
United Therapeutics (Ticker: UTHR) prepares to present new phase 3 clinical trial data for Tyvaso, an inhaled form of treprostinil aimed at treating idiopathic pulmonary fibrosis (IPF). The company al…
Tyvaso's Breakthrough in Respiratory Health: A Game Changer for Patients United Therapeutics makes headlines with its recent study demonstrating the efficacy of nebulized Tyvaso (treprostinil) in impr…
Tyvaso's Promising Impact on Lung Function Enhances United Therapeutics' Role in Respiratory Health Recent findings from a clinical study underscore the critical role of United Therapeutics’ nebulized…
Commitment to Employee Welfare: A Key Trend in the Healthcare Sector Recent industry reports underscore a significant trend in the corporate realm, particularly relevant for companies like United Ther…
BioPharma Breakthrough: United Therapeutics Expands Role in Lung Health United Therapeutics Corporation is on the forefront of innovation in the biotechnology sector, particularly in the development o…
United Therapeutics Advances Innovative Therapy for Pulmonary Arterial Hypertension United Therapeutics Inc. announces significant progress in its drug development for pulmonary arterial hypertension…
United Therapeutics Reports Strong Q4 Earnings Driven by Product Demand United Therapeutics Corp announces its fourth-quarter earnings, showcasing significant growth that aligns with the company’s str…
United Therapeutics Sees Strong Growth Amid Innovative Treatment Developments United Therapeutics announces impressive financial results for Q4 2026, boasting total revenues of $1.2 billion, a 15% inc…
United Therapeutics Reports Strong Q4 Earnings, Highlighting Growth in Innovative Therapies United Therapeutics (NASDAQ: UTHR) announces impressive financial performance for the fourth quarter, report…
United Therapeutics Sees Decrease in Short Interest, Signaling Investor Confidence United Therapeutics Corp, a key player in the biotechnology sector focused on developing innovative treatments for ch…
Artificial Intelligence's Transformative Role in Biotechnology United Therapeutics, a leading biotechnology company, operates at the intersection of healthcare innovation and advanced technology. As t…
United Therapeutics Prepares for Key Earnings Report Amid Biotech Innovations United Therapeutics is set to release its quarterly earnings report on October 29, 2025, a development that has attracted…
United Therapeutics Advances Pulmonary Medicine with TETON-2 Study Findings United Therapeutics Corporation (UTHR) makes significant strides in the treatment of idiopathic pulmonary fibrosis (IPF) wit…
United Therapeutics Reports Strong Second Quarter, Bolstering Commitment to Therapeutic Innovation United Therapeutics Corp (UTHR) demonstrates robust growth in its second-quarter financial results, s…
Innovative Growth and Strong Demand Define United Therapeutics' Second Quarter Performance United Therapeutics Corp (UTHR) demonstrates a robust financial performance in its second-quarter earnings re…
United Therapeutics: Navigating a Complex Market Landscape In recent months, United Therapeutics has emerged as a focal point of discussion among analysts, who provide a spectrum of ratings reflecting…
United Therapeutics: Focus on Advancements in Pulmonary Arterial Hypertension Treatments United Therapeutics is currently navigating a challenging environment as the company faces a notable decline in…
United Therapeutics Faces Market Challenges Amidst Industry Developments United Therapeutics, a leading biotechnology company focused on innovative therapies for chronic and life-threatening condition…
Innovative Treatment for Pulmonary Hypertension Gains FDA Approval In a significant development for patients suffering from pulmonary hypertension, the U.S. Food and Drug Administration (FDA) has gran…
Navigating Competitive Challenges: United Therapeutics’ Strategic Positioning United Therapeutics (UTHR) currently faces a complex landscape characterized by competitive pressures in the biopharmaceut…
United Therapeutics Advances Xenotransplantation with FDA Clearance for UKidney™ Trial United Therapeutics Corporation receives a significant boost in its mission to address the critical shortage of t…